STATEN ISLAND - Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) has revealed promising research results for its antibiotic candidate ibezapolstat, which is being prepared for international Phase 3 clinical trials to treat C. difficile Infection (CDI). The findings, presented at the International C. difficile Symposium, showcase ibezapolstat's unique interaction with its molecular target, potentially setting it apart from other antibiotics.
The research, conducted in collaboration with Leiden University Medical Center, provides insight into the molecular structure of ibezapolstat and its mechanism of action against DNA pol IIIC, a key bacterial enzyme. This understanding is critical for the rational design of new therapeutic compounds and supports Acurx's regulatory filings as ibezapolstat progresses toward commercialization.
Ibezapolstat has shown a lack of cross-resistance with other antibiotics and does not foster the emergence of resistant Enterococcus strains, including vancomycin-resistant variants. These properties could offer a significant advantage in the fight against antimicrobial resistance.
The company has reached an agreement with the FDA on key elements for the upcoming Phase 3 trials, including protocol design and primary efficacy analysis, which will be consistent with EMA requirements. The planned trial will enroll approximately 450 subjects to assess ibezapolstat's clinical cure rate and its potential to reduce CDI recurrence.
Acurx is also preparing to request regulatory guidance for clinical trials in the European Union, the United Kingdom, Japan, and Canada. Ibezapolstat has previously received FDA QIDP and Fast-Track Designation, highlighting its potential as a treatment for CDI.
The Phase 2 clinical trials demonstrated a high clinical cure rate for ibezapolstat, with favorable microbiome changes suggesting a reduced likelihood of CDI recurrence compared to vancomycin. These trials also provided valuable pharmacokinetic data and insights into bile acid metabolism associated with the treatment.
As Acurx moves forward with its development plans for ibezapolstat, the research outcomes are expected to guide the selection of product candidates for other high-priority, multi-drug resistant Gram-positive pathogens. The information in this article is based on a press release statement from Acurx Pharmaceuticals, Inc.
In other recent news, Acurx Pharmaceuticals reported a net loss of $4.1 million for the second quarter of 2024, with a cash reserve of $6.4 million. The company is gearing up for Phase 3 trials of its lead antibiotic candidate, ibezapolstat, and is actively seeking partnerships and non-dilutive funding options to cover the estimated $50 million cost. Acurx has also secured a new patent for ibezapolstat, which is valid until 2042.
Despite the significant net loss, the company remains optimistic about its financial sustainability, with funds expected to last until mid-2025 or mid-2026. This is due to a combination of existing cash reserves, potential partnerships, and other creative financing options. The company's readiness for Phase 3 trials, the new patent, and the increased interest in the antibiotic space are seen as positive developments.
The company is in active discussions with potential partners and has signed multiple confidentiality agreements. With these recent developments, Acurx Pharmaceuticals continues to navigate a critical phase in its growth, preparing for the costly Phase 3 trials while maintaining a healthy cash reserve into the mid-2020s.
InvestingPro Insights
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) is advancing to the critical Phase 3 clinical trials with its antibiotic candidate, ibezapolstat, and investors are closely watching the company's financial health and market performance. According to InvestingPro data, Acurx has a market capitalization of $30.38 million, which reflects the current valuation of the company in the market.
Investors should note that Acurx has been trading at a high Price / Book multiple of 8.86, which suggests that the market has high expectations for the company, despite its challenges. This is particularly relevant as the company does not pay dividends and is not expected to be profitable this year, as indicated by an analyst consensus on InvestingPro. With a P/E ratio of -1.62, the company's earnings do not currently justify its share price, a common scenario for early-stage biotech firms focusing on research and development.
One key InvestingPro Tip for ACXP is that the company holds more cash than debt on its balance sheet, which is a positive sign for investors as it suggests a lower risk of financial distress while the company continues to invest in its clinical trials. Additionally, the stock price has fared poorly over the last month, with a one-month price total return of -17.62%, which may present a buying opportunity for long-term investors who believe in the potential of ibezapolstat.
For readers interested in a deeper analysis, there are additional InvestingPro Tips available for Acurx Pharmaceuticals, which can shed more light on the company's financial standing and market performance. These tips can be accessed through InvestingPro's platform, which provides a comprehensive set of tools and data for investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.